CLAIMS

1. Use of varying concentrations of Calebin-A in the manufacture of a medicament to ~~induce lipolysis in mammalian adipocytes, restoring adipocyte size in the fat tissue of obese mammals, or treating~~ treat high fat diet (HFD) induced hepatic steatosis ~~in mammals.~~ associated with non alcoholic fatty liver disease wherein Calebin A attenuates hepatic inflammatory infiltration and hepatocellular ballooning degeneration.